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Jeong et al. 4 screened 494 acute leukemias and solid tumors and identified JAK1 mutation as a frequent event in T-ALL (3/11), whereas JAK3 mutations were only found in breast and gastric carcinoma. JAK3 mutations have been reported in a small number of hematopoietic neoplasms, including adult T-cell leukemia/lymphoma, 5 cutaneous T-cell lymphoma 6 and acute megakaryoblastic leukemia. 7 However, there have been no published data reporting JAK3 mutations in T-ALL. This is the first report describing JAK3 mutations in T-ALL. In all, 42 T-ALL cases were screened using a multiplex panel that covers point mutations in 31 genes relevant to hematological malignancies, including JAK1, JAK2 and JAK3. Primer extension products derived from PCR-amplified DNA samples were analyzed using MALDI-TOF (matrix-assisted, laser desorption/ionization time of flight) mass spectrometry (Sequenom Mass ARRAY system), as previously described. 8 Three patient samples had JAK3 mutations (7%), including two patients with R657Q mutations in exon 14 and one with an A573V mutation in exon 12. One of the patients with a JAK3 R657Q mutation had a JAK1 exon 15 R724H mutation as well. The JAK1 and JAK3 mutations were confirmed by Sanger sequence analysis. No JAK2 mutations were detected in our series. Detailed demographic, diagnostic and outcome data for these three patients are described in Table 1 .
To further document the relationship between the JAK3-mutant clone and disease status, we measured the JAK3-mutant allele burden and recorded blast counts at various time points including induction, remission and relapse (Table 2) . Notably, the JAK3 mutation was found in all relapsed samples, but not during remission, suggesting that the JAK3-mutant clone was the leukemic clone. Furthermore, our finding of detectable JAK3 mutations in the setting of a very low blast percentage (1%) by morphological and immunological analysis raises the possibility of using JAK3 mutation as a marker of MRD (minimal residual disease) in this group of patients. Detectable MRD, at the level of 41% blasts at the end of induction has extremely poor prognosis in ALL. Although there was concordance of JAK mutant allele burden and blast percentage in samples with relatively high blast frequency, four specimens with blast frequencies in the range of 1-5% exhibited mutant allele frequencies that were much higher. We have not established the linear range of the MALDI-TOF assays, and cannot rule out the possibility of over-estimation of mutant allele frequencies in these specimens. It is also possible that the blast count is decreased due to therapy, and the mutation is truly present in non-blast cells. In the latter case, the JAK mutation could provide an additional measure of disease burden to complement the blast count.
Other well-described mutations in T-ALL were detected in this series, including NOTCH1 mutations in 7/42 (16%) cases, FBXW7 in 3/42 (7%) cases and PTPN11 in 1/42 (2%) of the cases. However, none of these common mutations was found in the JAK3-mutant samples. In light of recent reports of activating IL7R mutations that encompass codon S185 in the extracellular region as well as insertion/deletions in the transmembrane region, 9,10 the JAK3-mutant samples were subjected to Sanger sequence analysis of IL7R exons 5 and 6. A T2444KAGS insertion/deletion within the transmembrane domain was found in specimen from patient 1 (diagnostic as well as relapse specimens), but was not detectable in remission specimens. Details are presented in Table 2 . Notably, the IL7R mutation was always present at a lower frequency than the JAK3 mutation. This discrepancy could be due to differences in assay sensitivity between Sequenom vs Sanger sequencing, but the difference persisted when both JAK3 and IL7R mutations were tested using Sanger sequencing. Because the diagnostic and relapse 1 samples were nearly homozygous for the JAK3 mutation (mutation frequencies of 86% and 97%, respectively) and heterozygous for the IL7R mutation, we believe that the IL7R mutant clone arose in a cell with the JAK3 mutation and that there are at least two clones in this patient: JAK3 R657Q/IL7R wild type and JAK3 R657Q/ IL7R T2444KAGS. A previously described polymorphism, T244I, 10 was detected in both diagnostic and remission specimens from patient 2, whereas no IL7R variants were detected in patient 3.
The JAK1 R724H, 11 JAK3 A573V 12 and JAK3 R657Q 13 mutations have all been demonstrated to confer gain of function, and the IL7R T2444KAGS variant is located in a region of the transmembrane domain that is a known mutation hotspot. Although the majority of IL7R mutations in this region result in the insertion of a Cys residue that is important for ligand-independent receptor dimerization and downstream signaling, approximately 10-20% of IL7R transmembrane variants lack this Cys residue and may activate the receptor through a different mechanism. 9, 10 Interestingly, in our series, both patients with JAK3 R657Q mutations harbored an additional mutation in either JAK1 or IL7R. To our knowledge, there have been no previous reports describing such concomitant mutations in any type of acute leukemia.
Although it has not been verified that the JAK3 and JAK1 or IL7R mutations are present in the same clone, it is possible that the mutant proteins could act cooperatively. In heteromeric cytokine receptor complexes, JAK3 binds to the common subunit, whereas JAK1 associates with the ligand-specific chain or the shared IL-2/IL-15 chain. JAK3 and JAK1 perform non-redundant roles in as much as constitutively active T-ALL. IL7R mutants selectively activate JAK1 but not JAK3, and require JAK1 but not JAK3 to activate STAT5. 10, 14 In the context of the IL2R, JAK3 and JAK1 transphosphorylate each other, but only JAK1 phosphorylates STAT5. Whereas the presence of JAK3 and JAK1 or IL7R mutants in the same patient is somewhat unexpected, there is precedent for double mutations affecting the same pathway in other cancers, such as RAS and BRAF mutations in melanoma. 8 We speculate that there is enhanced pathway activation with these co-existing gain-of-function mutations.
Current therapies achieve 5-year relapse-free survival rates of about 75% in children and 50% in adults with T-ALL. Complete remission rates are around 94% and the rate of relapse is around 30-40% at 2 years. However, two out of our three JAK3-positive T-ALL patients had multiple relapses in the first 5 years after diagnosis. In addition, the patient with both JAK1 and JAK3 mutations died within 18 months. The third patient has only had 12 months of clinical follow-up. Evaluation of a larger cohort of patients is clearly warranted to determine the potential prognostic value of the JAK3 mutations.
With increased understanding of the mechanisms of leukemic cell transformation, as well as the genetic influences on a patient's response to chemotherapy, we are close to an era of personalized therapy for ALL, in which therapy will be based on the unique molecular targets of individual patients. JAK and STAT5 inhibitors have been shown to significantly decrease the growth and viability of cells expressing activating JAK3 and IL7R mutants. 10, 13, 15 These results provide proof-of-principle evidence that JAK and STAT inhibitors could have therapeutic effects for patients whose leukemia has an associated activating JAK3 or IL7R mutation.
In conclusion, we describe for the first time the presence of JAK3 mutations in T-ALL. Our data support the inclusion of JAK3 as well as JAK1 and IL7R mutation testing in the routine clinical evaluation of T-ALL patients to identify candidates who may benefit from personalized targeted therapy.
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Michael Heinrich has equity interest in and is a consultant for Molecular MD. The other authors declare no conflict of interest. CD200 is a type-1a transmembrane cell-surface glycoprotein that is normally expressed in critical tissues such as the central nervous system and testis, as well as certain leukocytes, including T and B lymphocytes, where its role is to promote peripheral tolerance and protect immune privileged sites. 1 CD200 has no known intracellular signaling motif, but induces immunosuppression through engagement with CD200R, a cell-surface receptor homolog, which is expressed on leukocytes of myeloid lineage, including mast-cells, macrophages, basophils, dendritic cells as well as certain T-cell populations.
2 CD200, which is frequently overexpressed in acute myeloid leukemia (AML) patient blasts and associated with a worse outcome, 3 has the potential to induce the formation of CD4 þ CD25 þþ FoxP3 þ regulatory T cells (Tregs), 4 a subset of immunosuppressive T cells that are linked with a poor prognosis in AML. 5 Most importantly, Tregs have been documented to suppress the anti-leukemia response in vitro from AML patients, 6 suggesting that these cells have an important role in regulating AML patient tumor immunity. We therefore investigated whether CD200 protein expression on human AML blasts was associated with an increased frequency of Treg cells in AML using a cohort of 40 AML patients (at the point of diagnosis before to any treatment; Supplementary Table S1 for patient demographic). AML blast CD200 protein expression and patient Treg frequency was analyzed by flow cytometry (for full gating strategy, refer to Supplementary Figure S1 ). The data show that CD200 blast expression level correlated significantly with the frequency of Treg cells (Figure 1a ). This association was found to be independent of white blood cell count (Figure 1b) , suggesting that CD200 expression on AML blasts promotes Treg formation. We also examined whether CD200 expression was differentially expressed on AML blasts with a putative leukemic stem cell phenotype (CD34 þ CD38 À ), 7 but could find no evidence for this within the six samples examined (Supplementary Figure S2) .
Given that the depletion of Tregs has been shown to improve T-cell-mediated therapy, as well as improving antitumor activity in leukemia patients that are in complete remission; 8, 9 we investigated whether Tregs from CD200 hi patients were functionally immunosuppressive. We examined the ability of purified Tregs to suppress naïve responder T-cell (CD4 þ CD25 À ) proliferation following CD3/CD28 co-stimulation (refer to Supplementary Materials and Methods). The data demonstrate that Tregs isolated from CD200 hi AML patients were capable of suppressing T-cell proliferation at responder to Treg ratios of 41 to 0.01 (Figure 1c ). Reciprocal analysis of Tregs from CD200 lo patients could not be carried out because of the extremely low frequencies of these cells in CD200 lo patients (Figure 1d ). In fact, Treg frequencies in CD200 lo AML patients were uniformly lower than in healthy donor controls, suggesting that CD200 has an influence on Treg induction in this context.
Since mouse models have suggested that CD200-induced Tregs are likely to mediate Th1 immunosuppression, 10 a cytokine response with a prognostic link in leukemia, 11 we measured the Th1 cytokine response (TNFa, IL2 and IFNg production) in CD200 hi patients before and after Treg depletion. Representative flow cytometric plots confirmed Treg depletion using magnetic separation (Figure 2a) . However, removal of Tregs alone was insufficient to significantly improve the Th1 cytokine response as detected by intracellular cytokine staining (Figure 2b ). Elsewhere we report that, in addition to its known influence on Treg production, CD200 is also directly immunosuppressive through engagement with CD200R
